Purpose: AI’s role in accelerating drug development, from target identification to clinical trial... View more
PublicAI in Clinical Domain
Organizer:
Organized by
Group Description
Purpose: AI’s role in accelerating drug development, from target identification to clinical trial optimization.
Description:This group explores how AI and machine learning are transforming the pharmaceutical industry, enhancing efficiency and success rates across the entire drug discovery and development pipeline.
Intended Use:For pharmaceutical researchers, drug developers, AI developers, and academics to discuss specific AI algorithms and strategies impacting drug design, preclinical research, clinical trials, and drug repurposing.
Limitations: Not for general AI model development (that’s 1.3). Not for direct patient care applications. Focus is on AI within the pharmaceutical and drug discovery domain.
Key Activities:Sharing breakthroughs in AI-driven target identification.Discussing AI’s impact on optimizing clinical trial design and patient selection.Exploring AI for drug repurposing and accelerating R&D.Debating ethical considerations in AI-accelerated drug development.
Potential Users:Academic/Researcher, AI Innovator/Developer, Industry/Solution Provider (Pharma/Biotech).
Possible Discussions: “Using AI to identify novel drug targets for oncology,” “AI-powered prediction of drug toxicity,” “The role of AI in accelerating vaccine development.”
Please note:
This action will also remove this member from your connections and send a report to the site admin.
Please allow a few minutes for this process to complete.